Actively Recruiting
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
Led by TScan Therapeutics, Inc. · Updated on 2025-11-24
300
Participants Needed
12
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the specific targets of T cells involved in autoimmune diseases by studying tissues from patients with active organ inflammation caused by autoimmune conditions. The study aims to identify which T cells are activated and expanding in diseased tissues compared to blood or normal tissues. This information will help discover new peptide targets and their associated T cell receptors TCRs to develop potential new therapies for autoimmune diseases. Participants will provide tissue samples and matched blood samples during clinical procedures such as endoscopy, arthrocentesis, lumbar puncture, skin biopsy, bronchoscopy, or surgery, depending on their autoimmune condition. The study includes several groups covering diseases like Crohns disease, ulcerative colitis, celiac disease, ankylosing spondylitis, multiple sclerosis, scleroderma, systemic sclerosis, and other autoimmune diseases. Samples may come from excess clinical materials or research-specific biopsies, with the possibility of serial sampling over time. During the study, participants will undergo standard clinical procedures with collection of additional tissue or fluid samples and companion blood draws. Researchers will analyze these samples to identify peptide targets linked to disease-reactive T cells over a period of up to three years. The study includes comprehensive assessments of tissues and blood to understand T cell activity in autoimmune disorders, with monitoring of participant safety and no interventions beyond routine clinical care.
CONDITIONS
Brief Title
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older at time of informed consent
- Known or suspected diagnosis of autoimmune diseases including Crohn's disease, ulcerative colitis, celiac disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, multiple sclerosis, scleroderma, systemic sclerosis with pulmonary involvement, other autoimmune diseases, or evolving autoimmune disease
- Ability to understand and willingness to sign informed consent when required
- On disease-modifying treatments not known to be directly toxic to T cells, including certain NSAIDs, TNF-alpha antagonists, interleukin antagonists, interferons, CD20 antagonists, oral fumarates, S1PR modulators, and glatiramer acetate
- Appropriate candidate for biopsy, tissue sample, or biologic material collection during clinically indicated or research procedures
You will not qualify if you...
- Treatment with drugs known to be toxic to T cells that cannot be stopped for at least 4 weeks, including glucocorticoids, sulfasalazine, aminosalicylates, thiopurines, systemic JAK inhibitors, CD52 inhibitors, methotrexate, cladribine, teriflunomide
- Serious medical or psychiatric conditions that interfere with safety or informed consent
- Dementia, altered mental status, or psychiatric conditions preventing consent
- History of severe allergic reactions to local anesthetics or sedation medications if required for biopsy procedures
- Pregnant or nursing women
- Any other medical or psychiatric condition deemed hazardous for participation by treating clinician
Research Team
L
Laurie Barefoot
S
Shrikanta Chattopadhyay
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here